PMID- 14695703
OWN - NLM
STAT- MEDLINE
DCOM- 20040415
LR  - 20170309
IS  - 1598-9992 (Print)
IS  - 1598-9992 (Linking)
VI  - 42
IP  - 6
DP  - 2003 Dec
TI  - Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in 
      relation to CYP2C19 genotype.
PG  - 468-75
AB  - BACKGROUND/AIMS: Genetic polymorphism of cytochrome P450 CYP2C19 influences the 
      efficacy of proton pump inhibitor (PPI) in Helicobacter pylori (H. pylori) 
      eradication therapy. We investigated the difference in the cure rates of H. 
      pylori infection by triple (rabeprazole plus amoxacillin and clarithromycin) 
      therapy in relation to CYP2C19 genotype status. METHODS: One hundred and sixteen 
      H. pylori infected patients with gastric ulcer and duodenal ulcer completed the 
      triple therapy with 10 mg of rabeprazole b.i.d., 1,000 mg amoxacillin b.i.d. and 
      500 mg of clarithromycin b.i.d. for one week. The genotype of CYP2C19 was 
      determined by a PCR-restriction fragment length polymorphism method. RESULTS: 
      According to the univariate analysis, heterozygous extensive metabolizers (hetero 
      EMs) and poor metabolizers (PMs) showed the highest (87.0%) and the lowest 
      (80.0%) eradication rates, respectively. The difference in the therapeutic 
      efficacy of rabeprazole among the different CYP2C19 genotypes was insignificant. 
      With regard to gender, age and smoking history in relation to eradication rate, a 
      statistical significance was noted only with age with odds ratio of 1.063 and 
      p-value of 0.0202. CONCLUSIONS: In the eradication therapy of H. pylori, no 
      statistically significant difference in therapeutic efficacy of rabeprazole was 
      found among different CYP2C19 genotypes.
FAU - Lee, Sang Bae
AU  - Lee SB
AD  - Department of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam-si, 
      Gyeonggi-do, Korea.
FAU - Park, Sang Jong
AU  - Park SJ
FAU - Ryu, Ji Kon
AU  - Ryu JK
FAU - Lee, Jin Kwang
AU  - Lee JK
FAU - Kim, Hoi Jin
AU  - Kim HJ
FAU - Bae, Jin Soo
AU  - Bae JS
FAU - Jung, Hyun Seung
AU  - Jung HS
FAU - Park, Sil Moo
AU  - Park SM
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - H1250JIK0A (Clarithromycin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Aged
MH  - Amoxicillin/administration & dosage
MH  - Anti-Bacterial Agents/administration & dosage
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Aryl Hydrocarbon Hydroxylases/*genetics
MH  - Benzimidazoles/*administration & dosage
MH  - Clarithromycin/administration & dosage
MH  - Cytochrome P-450 CYP2C19
MH  - Drug Therapy, Combination
MH  - Duodenal Ulcer/drug therapy/*genetics/microbiology
MH  - Female
MH  - Genotype
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mixed Function Oxygenases/*genetics
MH  - Omeprazole/analogs & derivatives
MH  - *Proton Pump Inhibitors
MH  - Rabeprazole
MH  - Stomach Ulcer/drug therapy/*genetics/microbiology
EDAT- 2003/12/27 05:00
MHDA- 2004/04/16 05:00
CRDT- 2003/12/27 05:00
PHST- 2003/12/27 05:00 [pubmed]
PHST- 2004/04/16 05:00 [medline]
PHST- 2003/12/27 05:00 [entrez]
AID - 200312468 [pii]
PST - ppublish
SO  - Korean J Gastroenterol. 2003 Dec;42(6):468-75.